Eli Lilly Surges Past Projections, Boosts Forecast Amid Sales Boom

WHO:

CNBC - Eli Lilly is a pharmaceutical giant led by CEO Dave Ricks.

WHAT:

CNBC - Eli Lilly reported second-quarter earnings of $8.38 adjusted earnings per share, surpassing the expected $6.01.

CNBC - The company reported revenue of $22.97 billion, exceeding the expected $20.73 billion.

CNBC - Eli Lilly raised its full-year revenue forecast to between $85 billion and $87 billion, up from a previous guidance of $82 billion to $85 billion.

CNBC - The adjusted profit guidance was raised to between $35.50 and $36.50 per share, compared to a previous outlook of $35.50 to $37 per share.

CNBC - Mounjaro's worldwide revenue rose 91% to $9.94 billion for the quarter, including U.S. sales of $4.8 billion.

CNBC - Zepbound generated $4.93 billion in revenue for the second quarter, a 46% increase from the previous year.

CNBC - Foundayo, a newly launched obesity pill, generated $98 million in sales for the second quarter.

WHERE:

CNBC - Eli Lilly holds a 60.9% share of the U.S. obesity and diabetes drug market.

WHEN:

CNBC - Eli Lilly's newly launched obesity pill, Foundayo, won U.S. approval in April.

WHY:

CNBC - The surge in sales for Zepbound and Mounjaro is attributed to resilient demand despite lower prices for the medications in the U.S.

CNBC - Demand for Mounjaro is particularly strong in middle-income countries such as Brazil, China, and India.

HOW:

CNBC - Eli Lilly is executing a historic M&A spending spree, including a recent deal to buy a psychedelics drugmaker and plans to purchase three vaccine makers.

(UPDATED August 5, 2026 16:17 UTC)

Eli Lilly, led by CEO Dave Ricks, has reported impressive second-quarter earnings, with adjusted earnings per share hitting $8.38, far exceeding the expected $6.01, and revenue reaching $22.97 billion, surpassing forecasts of $20.73 billion. The company has also raised its full-year revenue forecast to between $85 billion and $87 billion, while its newly launched obesity pill, Foundayo, generated $98 million in sales after winning U.S. approval in April. Eli Lilly holds a dominant 60.9% share of the U.S. obesity and diabetes drug market, benefiting from strong demand for its products like Mounjaro and Zepbound, even amid price reductions.